<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202266</url>
  </required_header>
  <id_info>
    <org_study_id>B2911002</org_study_id>
    <nct_id>NCT01202266</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study Of PF-05161704 In Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Pf-05161704 After Administration Of Multiple Escalating Oral Doses In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability and
      pharmacokinetics of multiple escalating oral doses of PF-05161704 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated on October 29, 2010 due to gastrointestinal adverse events.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability endpoints evaluated by adverse event monitoring, laboratory values, cardiovascular monitoring</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Endpoints: single dose and steady state pharmacokinetics of PF-05161704 and its metabolite PF-05200145. Urinary recovery will also be assessed for PF-05161704 and PF-05200145</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Endpoints: Absolute value and change from Day 0 baseline in postprandial GLP-1. Postprandial plasma PYY, triglycerides and apoB48. Absolute value and change from baseline in apoB100 and VLDL</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Parameters: absolute value and change from Day 0 baseline in concentrations of fasting serum lipids and body weight</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>5 mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned dose: may be modified based on emerging PK and safety data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned dose: may be modified based on emerging PK and safety data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned dose: may be modified based on emerging PK and safety data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>xx mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned dose and dosing regimen will be determined based on emerging PK and safety data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>xxx mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose will be determined based on data from previous 5 arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>yy mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose will be determined based on data from previous 6 arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>yyy mg PF-05161704 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose will be determined based on data from previous 7 arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner</description>
    <arm_group_label>5 mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner</description>
    <arm_group_label>15 mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner</description>
    <arm_group_label>50 mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner</description>
    <arm_group_label>150 mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast</description>
    <arm_group_label>xx mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast</description>
    <arm_group_label>xxx mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast</description>
    <arm_group_label>yy mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05161704 or Placebo</intervention_name>
    <description>PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast</description>
    <arm_group_label>yyy mg PF-05161704 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female (non-childbearing potential) subjects between the ages of
             18 and 55 years, inclusive

          -  Body Mass Index (BMI) of 24.5 to 35.5 kg/m2 and a total body weight &gt;50 kg (110 lbs.)

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy).

          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14
             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.

          -  History or evidence of habitual use of tobacco or nicotine containing products within
             3 months of screening or positive cotinine test at screening or Day -1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2911002&amp;StudyName=A%20Multiple%20Dose%20Study%20Of%20PF-05161704%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2010</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Multiple Ascending Dose</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Safety and Tolerability</keyword>
  <keyword>PK</keyword>
  <keyword>Healthy Subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

